Immunogenicity and Safety of Reduced-Dose Intradermal Vs Intramuscular Influenza Vaccines: A Systematic Review and Meta-analysis

Overview

Journal JAMA Netw Open

Publisher American Medical Association

Specialty General Medicine

Date 2021 Feb 9

PMID 33560425

Citations 25

Authors

Oluwaseun Egunsola

Fiona Clement

John Taplin

Liza Mastikhina

Joyce W Li

Diane L Lorenzetti

Laura E Dowsett

Tom Noseworthy

Affiliations

Soon will be listed here.

Abstract

Importance: Low-dose intradermal influenza vaccines could be a suitable alternative to full intramuscular dose during vaccine shortages.

Objective: To compare the immunogenicity and safety of the influenza vaccine at reduced or full intradermal doses with full intramuscular doses to inform policy design in the event of vaccine shortages.

Data Sources: MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched for studies published from 2010 until June 5, 2020.

Study Selection: All comparative studies across all ages assessing the immunogenicity or safety of intradermal and intramuscular influenza vaccinations were included.

Data Extraction And Synthesis: Data were extracted by a single reviewer and verified by a second reviewer. Discrepancies between reviewers were resolved through consensus. Random-effects meta-analysis was conducted.

Main Outcomes And Measures: Primary outcomes included geometric mean titer, seroconversion, seroprotection, and adverse events.

Results: A total of 30 relevant studies were included; 29 studies were randomized clinical trials with 13 759 total participants, and 1 study was a cohort study of 164 021 participants. There was no statistically significant difference in seroconversion rates between the 3-µg, 6-µg, 7.5-µg, and 9-µg intradermal vaccine doses and the 15-µg intramuscular vaccine dose for each of the H1N1, H3N2, and B strains, but rates were significantly higher with the 15-µg intradermal dose compared with the 15-µg intramuscular dose for the H1N1 strain (rate ratio [RR], 1.10; 95% CI, 1.01-1.20) and B strain (RR, 1.40; 95% CI, 1.13-1.73). Seroprotection rates for the 9-µg and 15-µg intradermal doses did not vary significantly compared with the 15-µg intramuscular dose for all the 3 strains, except for the 15-µg intradermal dose for the H1N1 strain, for which rates were significantly higher (RR, 1.05; 95% CI, 1.01-1.09). Local adverse events were significantly higher with intradermal doses than with the 15-µg intramuscular dose, particularly erythema (3-µg dose: RR, 9.62; 95% CI, 1.07-86.56; 6-µg dose: RR, 23.79; 95% CI, 14.42-39.23; 9-µg dose: RR, 4.56; 95% CI, 3.05-6.82; 15-µg dose: RR, 3.68; 95% CI, 3.19-4.25) and swelling (3-µg dose: RR, 20.16; 95% CI, 4.68-86.82; 9-µg dose: RR, 5.23; 95% CI, 3.58-7.62; 15-µg dose: RR, 3.47 ; 95% CI, 2.21-5.45). Fever and chills were significantly more common with the 9-µg intradermal dose than the 15-µg intramuscular dose (fever: RR, 1.36; 95% CI, 1.03-1.80; chills: RR, 1.24; 95% CI, 1.03-1.50) while all other systemic adverse events were not statistically significant for all other doses.

Conclusions And Relevance: These findings suggest that reduced-dose intradermal influenza vaccination could be a reasonable alternative to standard dose intramuscular vaccination.

Citing Articles

Intradermal delivery of SARS-CoV-2 RBD3-Fc mRNA vaccines via a needle-free injection system induces robust immune responses in rats.

Wang C, Tang X, Jiang C, Zhang Y, Han B, Sun Y Front Immunol. 2025; 16:1530736.

PMID: 40034698 PMC: 11872709. DOI: 10.3389/fimmu.2025.1530736.

DNA vaccines as promising immuno-therapeutics against cancer: a new insight.

Shariati A, Khezrpour A, Shariati F, Afkhami H, Yarahmadi A, Alavimanesh S Front Immunol. 2025; 15:1498431.

PMID: 39872522 PMC: 11769820. DOI: 10.3389/fimmu.2024.1498431.

The Relationship between Immunogenicity and Reactogenicity of Seasonal Influenza Vaccine Using Different Delivery Methods.

Gromer D, Plikaytis B, McCullough M, Wimalasena S, Rouphael N Vaccines (Basel). 2024; 12(7).

PMID: 39066447 PMC: 11281354. DOI: 10.3390/vaccines12070809.

Phase 1, randomized, rater and participant blinded placebo-controlled study of the safety, reactogenicity, tolerability and immunogenicity of H1N1 influenza vaccine delivered by VX-103 (a MIMIX microneedle patch [MAP] system) in healthy adults.

Garg N, Tellier G, Vale N, Kluge J, Portman J, Markowska A PLoS One. 2024; 19(6):e0303450.

PMID: 38843267 PMC: 11156369. DOI: 10.1371/journal.pone.0303450.

Microneedle patch with pure drug tips for delivery of liraglutide: pharmacokinetics in rats and minipigs.

Lin H, Liu J, Hou Y, Yu Z, Hong J, Yu J Drug Deliv Transl Res. 2024; 15(1):216-230.

PMID: 38619705 DOI: 10.1007/s13346-024-01582-1.

References

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Frenck Jr R, Belshe R, Brady R, Winokur P, Campbell J, Treanor J . Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults. Vaccine. 2011; 29(34):5666-74. PMC: 3150501. DOI: 10.1016/j.vaccine.2011.06.010. View

Ansaldi F, Durando P, Icardi G . Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement. Expert Opin Biol Ther. 2011; 11(3):415-27. DOI: 10.1517/14712598.2011.557658. View

Camilloni B, Basileo M, Di Martino A, Donatelli I, Iorio A . Antibody responses to intradermal or intramuscular MF59-adjuvanted influenza vaccines as evaluated in elderly institutionalized volunteers during a season of partial mismatching between vaccine and circulating A(H3N2) strains. Immun Ageing. 2014; 11:10. PMC: 4032355. DOI: 10.1186/1742-4933-11-10. View

La Montagne J, Fauci A . Intradermal influenza vaccination--can less be more?. N Engl J Med. 2004; 351(22):2330-2. DOI: 10.1056/NEJMe048314. View

Ansaldi F, Canepa P, Ceravolo A, Valle L, De Florentiis D, Oomen R . Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses. Vaccine. 2012; 30(18):2908-13. DOI: 10.1016/j.vaccine.2012.02.003. View

Levin Y, Kochba E, Hung I, Kenney R . Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future. Hum Vaccin Immunother. 2015; 11(4):991-7. PMC: 4514308. DOI: 10.1080/21645515.2015.1010871. View

Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View

Romani N, Flacher V, Tripp C, Sparber F, Ebner S, Stoitzner P . Targeting skin dendritic cells to improve intradermal vaccination. Curr Top Microbiol Immunol. 2011; 351:113-38. PMC: 4285659. DOI: 10.1007/82_2010_118. View

10.

Chuaychoo B, Wongsurakiat P, Nana A, Kositanont U, Maranetra K . The immunogenicity of intradermal influenza vaccination in COPD patients. Vaccine. 2010; 28(24):4045-51. DOI: 10.1016/j.vaccine.2010.04.006. View

11.

Hung I, Zhang A, To K, Chan J, Li P, Wong T . Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial. Lancet Infect Dis. 2015; 16(2):209-18. DOI: 10.1016/S1473-3099(15)00354-0. View

12.

Ansaldi F, Orsi A, De Florentiis D, Parodi V, Rappazzo E, Coppelli M . Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60: evaluation of immunogenicity, cross-protection, safety and tolerability. Hum Vaccin Immunother. 2013; 9(3):591-8. PMC: 3891716. DOI: 10.4161/hv.23240. View

13.

Veroniki A, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G . Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 2015; 7(1):55-79. PMC: 4950030. DOI: 10.1002/jrsm.1164. View

14.

Kunisaki K, Janoff E . Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009; 9(8):493-504. PMC: 2775097. DOI: 10.1016/S1473-3099(09)70175-6. View

15.

Puig-Barbera J, Natividad-Sancho A, Calabuig-Perez J, Lluch-Rodrigo J, Pastor-Villalba E, Martinez-Ubeda S . Intradermal and virosomal influenza vaccines for preventing influenza hospitalization in the elderly during the 2011-2012 influenza season: a comparative effectiveness study using the Valencia health care information system. Vaccine. 2014; 32(42):5447-54. DOI: 10.1016/j.vaccine.2014.07.095. View

16.

Chuaychoo B, Kositanont U, Rittayamai N, Niyomthong P, Songserm T, Maranetra K . The immunogenicity of the intradermal injection of seasonal trivalent influenza vaccine containing influenza A(H1N1)pdm09 in COPD patients soon after a pandemic. Hum Vaccin Immunother. 2016; 12(7):1728-37. PMC: 4964808. DOI: 10.1080/21645515.2016.1149276. View

17.

Chen W, Kozlovsky B, Effros R, Grubeck-Loebenstein B, Edelman R, Sztein M . Vaccination in the elderly: an immunological perspective. Trends Immunol. 2009; 30(7):351-9. PMC: 3739436. DOI: 10.1016/j.it.2009.05.002. View

18.

Boonnak K, Dhitavat J, Thantamnu N, Kosoltanapiwat N, Auayporn M, Jiang L . Immune responses to intradermal and intramuscular inactivated influenza vaccine among older age group. Vaccine. 2017; 35(52):7339-7346. DOI: 10.1016/j.vaccine.2017.10.106. View

19.

Gongal G, Sampath G . Introduction of intradermal rabies vaccination - A paradigm shift in improving post-exposure prophylaxis in Asia. Vaccine. 2018; 37 Suppl 1:A94-A98. DOI: 10.1016/j.vaccine.2018.08.034. View

20.

Gorse G, Falsey A, Johnson C, Morrison D, Fried D, Ervin J . Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age. Vaccine. 2013; 31(50):6034-40. DOI: 10.1016/j.vaccine.2013.09.012. View